- Home
- Companies
- Theralase Technologies Inc.
- Products
- Theralase - Anti-Cancer Therapy (“ACT”) ...
Theralase - Anti-Cancer Therapy (“ACT”) Technology
Theralase is laser focused on advancing the cutting-edge Anti-Cancer Therapy (“ACT”) towards commercialization, providing an alternative treatment methodology for Non-Muscle Invasive Bladder Cancer (“NMIBC”) patients globally. Theralase is dedicated to safely and effectively destroying cancer through the research, development and commercialization of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations.
ACT uses Photo Dynamic Compounds ("PDCs") (light-sensitive compounds) that when exposed to laser light are able to produce a violent form of oxygen known as singlet oxygen or Reactive Oxygen Species (“ROS”), which causes oxidative stress to cancer cells and induces Immunogenic Cell Death ("ICD").
Theralase® through its research, development and collaboration with world-renowned researchers has enhanced and modernized traditional PDCs, optimizing the technology and increasing the potential of PDCs to treat a broad range of diseases and overcome the safety and efficacy limitations of current cancer treatments.
Theralase® is conducting a pivotal Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study, with a primary endpoint of efficacy, secondary endpoint of duration of efficacy and tertiary endpoint of safety.
Theralase is conducting preclinical research in using its patented PDCs in the treatment of Glio Blastoma Multiforme (“GBM”) ( a deadly form of brain cancer) and Non-Small Cell Lung Cancer (“NSCLC”).